CAESAREA, Israel--(BUSINESS WIRE)--Mazor Robotics, Ltd. (TASE:MZOR; NASDAQ GM:MZOR), a developer of innovative surgical guidance systems and complementary products, announces the first presentation of data for Mazor’s PROlif™ Lateral solution, and the first time the procedure was shown on a cadaver at a medical conference. Both occurred last week during the Society for Minimally Invasive Spine Surgery (SMISS) Global Forum ’15 in Las Vegas.
“The Renaissance Guidance System easily integrates into my existing operating workflow and when using PROlif, it saves 45-60 minutes of anesthesia- and surgical time per case”Tweet this
A podium presentation entitled, Comparison Of Fluoro-guided vs. Robotic-guided Single-position Lateral Interbody Fusion and Posterior Fixation—A Preliminary Report, reported fluoroscopy time per screw was reduced by approximately one-third when Mazor Robotics technology was used. Neurosurgeon J. Alex Thomas, MD also reported zero revisions in those cases compared to three revisions in the fluoro-guided group.
In addition to the clinical data presented, SMISS Co-Chairman Kornelis Poelstra, MD, PhD, also led a Cadaver Workshop to demonstrate that PROlif is the only true single position solution for circumferential spinal fusion by using the Renaissance system to place pedicle screws in the lateral decubitus position.
“The Renaissance Guidance System easily integrates into my existing operating workflow and when using PROlif, it saves 45-60 minutes of anesthesia- and surgical time per case,” said Dr. Poelstra. “This improved efficiency means for us a clinically significant reduction in complication risk, in addition to the economic benefits for our institution. It typically amounts to enough time savings over two cases that I can perform an additional surgery that same day without ever compromising patient outcomes.”
“The interest we have seen in our PROlif Lateral solution illustrates that it is quickly gaining momentum and its value is being seen by many in the industry,” said Ori Hadomi, Chief Executive Officer of Mazor Robotics. “Mazor’s mission to heal through innovation is being realized when we introduce new solutions that improve both the patient and surgeon experience, as Dr. Poelstra has stated.”
PROlif™ Lateral is a solution to enable the guided placement of pedicle screws while the patient is in lateral decubitus position to reduce OR time by eliminating the need to flip the patient into prone position after an extreme lateral procedure.
Mazor Robotics (TASE:MZOR; NASDAQGM:MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the interest in the Company’s PROlif Lateral solution and its benefits, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.